共 29 条
Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC
被引:54
作者:
George, Jonathan R.
[1
]
Henderson, Ying C.
[2
]
Williams, Michelle D.
[3
]
Roberts, Dianna B.
[2
]
Hei, Hu
[2
]
Lai, Stephen Y.
[2
,4
]
Clayman, Gary L.
[2
,5
]
机构:
[1] Univ Calif San Francisco, Med Ctr, Head & Neck Surg Oncol & Head & Neck Endocrine Su, San Francisco, CA 94143 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
关键词:
PAPILLARY THYROID-CARCINOMA;
V600E MUTATION;
BRAF(V600E) MUTATION;
FOLLOW-UP;
CANCER;
RECURRENCE;
SURVIVAL;
PREDICTS;
D O I:
10.1210/jc.2015-2690
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Context: Papillary thyroid carcinoma (PTC) carrying the BRAF mutation has been reported to be associated with high recurrence and potentially increased mortality. PTC carrying the TERT promoter mutation has been associated with older age, recurrence, and aggressive disease. Objective: The objective of this study was to determine the association of BRAF and TERT promoter gene alterations with recurrence and survival in a high-risk population. Design: Genomic DNA was analyzed for the BRAF mutation from 256 persistent/recurrent PTC (p/rPTC; 202 new, 54 previously reported) and for the TERT promoter mutation and polymorphism (242 p/rPTC). Two-tailed Fisher exact tests or the Pearson chi(2) test were performed for the associations between mutations and other variables. Overall and disease-free survivals were compared by log rank tests on Kaplan-Meier plots and by Cox regression analysis. TERT promoter constructs were tested in PTC cell lines to determine their activities in these cells. Results: BRAF V600E mutation was identified in 235 of 256 (91.8%), TERT promoter mutation at -124 was detected in 77 of 242 (31.8%), and TERT promoter polymorphism at -245 was found in 113 of 242 (46.7%) p/rPTC patients. A significant difference in survival was found in p/rPTC patients with the TERT promoter mutation, which also displayed increased activity in vitro as compared to the nonmutated promoter sequence. No association was noted between the BRAF mutation or TERT promoter polymorphism and recurrence or survival. A drawback of our study could be the limited number of patients with nonmutated BRAF (21 of 256 [8.2%]). Conclusions: Mutation in the TERT promoter, but not in BRAF, was associated with decreased survival in 19 (24.7%) p/rPTC patients who died of disease and in 38 (49.4%) p/rPTC patients who died at last contact. The presence or absence of the BRAF mutation and TERT promoter polymorphism, however, was not significantly correlated with survival.
引用
收藏
页码:E1550 / E1559
页数:10
相关论文